Compare Dow Jones Industrial Average ETF (DIA) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Jones Industrial Average ETF vs Gilead Sciences, Inc. — how do they compare? Dow Jones Industrial Average ETF trades at $537.94, while Gilead Sciences, Inc. trades at $135.34 (market cap $168.35B). The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while Dow Jones Industrial Average ETF pays none, and Dow Jones Industrial Average ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| DIA | GILD | |
|---|---|---|
52-Week High | $542.79 | $155.80 |
52-Week Low | $444.64 | $110.56 |
Market Cap | — | $168.35B |
Sector | — | Health |
Enterprise Value | — | $191.42B |
Dividend Yield | — | 2.42% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
